Allison Rosenthal

Allison Rosenthal is an accomplished executive in the biopharmaceutical sector, currently serving as Chief Commercial Officer at Lykos Therapeutics since April 2024, where responsibilities include strategic partnership and guidance for the executive leadership and Board of Directors. Previously, from July 2020 to March 2024, Allison was the VP, Commercial Franchise Head for CNS at Otsuka Pharmaceutical Companies (U.S.), leading a team of 800 in the US CNS portfolio strategy. Prior experience includes being General Manager at Otsuka Canada Pharmaceutical Inc. from April 2012 to July 2020, where oversight encompassed operations, strategic planning, and financial performance. Allison's tenure at Bristol-Myers Squibb included roles such as Vice-President of the Virology Immunology Business Unit, where revenue exceeded $150M, and Commercial Director for Immunology, focusing on product re-launch strategies. Educational qualifications include an Institute Certified Director designation from the University of Toronto - Rotman School of Management, alongside MSc and BSc degrees in Anatomy from McGill University.